MedTrace Logo

Switching From Oral Bisphosphonates to Bazedoxifene to Evaluate Effects on Bone Mineral Density in Postmenopausal Women

NCT02090400 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2015-09-09

No results posted yet for this study

Summary

The aim of this study is see the changes in bone mineral density after discontinuation or stop the use of bisphosphonates and make the switch to bazedoxifene).

Conditions

  • Osteoporosis, Postmenopausal

Interventions

DRUG

Bazedoxifene

20 mg Oral daily for 12 months

DRUG

Calcium/Vit D

Calcium 500 mg / 400 IU Vit D

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Instituto Palacios

    lead OTHER

Principal Investigators

  • Santiago Palacios, MD

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
55 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-05-31
Primary Completion
2015-07-31
Completion
2015-07-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02090400 on ClinicalTrials.gov